Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 1/2014

01-02-2014 | Letter to the Editor

Diabetes mellitus associated with clomipramine treatment: a retrospective analysis

Authors: Nicola Mumoli, Massimo Cocciolo, Josè Vitale, Marco Mantellassi, Silvia Sabatini, Lisa Gambaccini, Marco Cei

Published in: Acta Diabetologica | Issue 1/2014

Login to get access

Abstract

In this retrospective analysis, we analyzed all clinical record data in our Medical Division between January 2005 and December 2006 to evaluate an association between clomipramine treatment and glucose intolerance. Of 1997 patients, 154 (7.7 %) had diabetes and 525 (26.3 %) had depression. Diabetes prevalence was significantly higher in patients treated with clomipramine than in patients not treated [odds ratio 3.9, (2.2–7.0), p < 0.00001], independently by age and BMI. A possible causal role needs to be investigated in a prospective way.
Literature
1.
Paulmann N, Grohmann M, Voigt JP, Bert B, Vowinckel J, Bader M, Skelin M, Jevsek M, Fink H, Rupnik M, Walther DJ (2009) Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol 7(10):e1000229PubMedCentralPubMedCrossRef
2.
3.
Mezuk B, Eaton WW, Albrecht S, Golden SH (2008) Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 31(12):2383–2390PubMedCrossRef
4.
Rubin RR, Ma Y, Peyrot M, Marrero DG, Price DW, Barrett-Connor E, Knowler WC, Diabetes Prevention Program Research Group (2010) Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care 33(12):2549–2551PubMedCrossRef
5.
Pan A, Sun Q, Okereke OI, Rexrode KM, Rubin RR, Lucas M, Willett WC, Manson JE, Hu FB (2012) Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia 55(1):63–72PubMedCentralPubMedCrossRef
Metadata
Title
Diabetes mellitus associated with clomipramine treatment: a retrospective analysis
Authors
Nicola Mumoli
Massimo Cocciolo
Josè Vitale
Marco Mantellassi
Silvia Sabatini
Lisa Gambaccini
Marco Cei
Publication date
01-02-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-013-0500-z

Other articles of this Issue 1/2014

Acta Diabetologica 1/2014 Go to the issue

Original Article

The effect of insulin resistance on postprandial triglycerides in Korean type 2 diabetic patients

Case Report

A case of esomeprazole-induced transient diabetes and hepatitis: the role of liver inflammation in the pathogenesis of insulin resistance

Short Communication

Hydrogen sulfide induces heme oxygenase-1 in human kidney cells

Original Article

Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials

Original Article

Low density lipoprotein receptor–related protein 1 is upregulated in epicardial fat from type 2 diabetes mellitus patients and correlates with glucose and triglyceride plasma levels

Original Article

Resting heart rate predicts metabolic syndrome in apparently healthy non-obese Japanese men
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits